Hypercholesterolemia is a major risk factor for the late-onset form of Alzheimer disease (AD). Loss-of-function (LOF) mutations of PCSK9 and PCSK9 inhibitors lower low-density lipoprotein cholesterol (LDL-C) and have been associated with a reduced risk of cardiovascular disease. The aim of this study was to examine the effect of PCSK9 LOF variants on risk and age of onset of AD.
Methods:
A total of 878 participants (410 controls and 468 AD cases) from the Quebec Founder Population were included in the study.
Results:
Fifty-four (6.2%) participants carried the R46L mutation, whereas 226 (26.2%) participants carried the InsLEU mutation. There was no protective or no deleterious effect of carrying PCSK9 LOF mutations on AD prevalence nor on age of onset, even when stratified by apolipoprotein E epsilon 4 genotype or by gender.
Conclusion:
Our data indicate that carrying PCSK9 LOF mutations has a neutral effect on neurocognitive health and the prevalence of AD.
CriminsJLPoolerAPolydoroMLuebkeJISpires-JonesTL. The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer’s disease. Ageing Res Rev. 2013;12(3):757–763.
3.
SilvaTTeixeiraJRemiãoFBorgesF. Alzheimer’s disease, cholesterol, and statins: the junctions of important metabolic pathways. Angew Chem Int Ed Engl. 2013;52(4):1110–1121.
4.
BrookmeyerRJohnsonEZiegler-GrahamKArrighiHM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–191.
TellecheaPPujolNEsteve-BellochP. Early-and late-onset Alzheimer disease: are they the same entity? [published online ahead of print November 2015]. Neurologia. pii:S0213–4853(15)00210–00218. doi:10.1016/j.nrl.2015.08.002.
7.
PoirierJDavignonJBouthillierDKoganSBertrandPGauthierS. Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet. 1993;342(8873):697–699.
8.
Cedazo-MínguezACowburnRF. Apolipoprotein E: a major piece in the Alzheimer’s disease puzzle. J Cell Mol Med. 2001;5(3):254–266.
9.
KivipeltoMHelkalaELLaaksoMP. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447–1451.
10.
WanamakerBLSwigerKJBlumenthalRSMartinSS. Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol. 2015;38(4):243–250.
11.
FonsecaACResendeROliveiraCRPereiraCM. Cholesterol and statins in Alzheimer’s disease: current controversies. Exp Neurol. 2010;223(2):282–293.
12.
SolomonAKivipeltoMWolozinBZhouJWhitmerRA. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009;28(1):75–80.
13.
KivipeltoMHelkalaELLaaksoMP. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149–155.
14.
WolozinBKellmanWRuosseauPCelesiaGGSiegelG. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57(10):1439–1443.
15.
HaagMDHofmanAKoudstaalPJStrickerBHBretelerMM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13–17.
16.
BettermannKArnoldAMWilliamsonJ. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis. 2012;21(6):436–444.
17.
LeducVDe BeaumontLThérouxL. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study. Mol Psychiatry. 2015;20(7):867–873.
18.
McGuinnessBCraigDBullockRPassmoreP. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;(1):CD003160. doi:10.1002/14651858.CD003160.pub3.
19.
FeldmanHHDoodyRSKivipeltoM. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956–964.
20.
SeidahNGBenjannetSWickhamL. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100(3):928–933.
21.
AbifadelMVarretMRabèsJP. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156.
22.
AwanZBaassAGenestJ. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia. Clin Chem. 2014;60(11):1380–1389.
23.
AwanZDelvinEELevyE. Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype. Can J Cardiol. 2013;29(8):927–933.
24.
SaavedraYGDufourRDavignonJBaassA. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study. Arterioscler Thromb Vasc Biol. 2014;34(12):2700–2705.
25.
CohenJCBoerwinkleEMosleyTHJrHobbsHH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–1272.
26.
CohenJPertsemlidisAKotowskiIKGrahamRGarciaCKHobbsHH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–165.
27.
MayneJOoiTCRaymondA. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Dis. 2013;12:70. doi:10.1186/1476-511X-12-70.
SwigerKJMartinSS. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug Saf. 2015;38(6):519–526.
30.
HassanM. OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events. Glob Cardiol Sci Pract. 2015;2015(2):20. doi:10.5339/gcsp.2015.20. eCollection 2015.
31.
GiuglianoRPMachFZavitzK. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633–643.
32.
RobinsonJGRosensonRSFarnierM. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol. 2017;69(5):471–482.
33.
BetardCKesslingAMRoyMChamberlandALussier-CacanSDavignonJ. Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. Hum Genet. 1992;88(5):529–536.
34.
Roy-GagnonMHMoreauCBhererC. Genomic and genealogical investigation of the French Canadian founder population structure. Hum Genet. 2011;129(5):521–531.
35.
KhachaturianZS. Diagnosis of Alzheimer’s disease. Arch Neurol. 1985;42(11):1097–1105.
ShibataNOhnumaTHigashiS. No genetic association between PCSK9 polymorphisms and Alzheimer’s disease and plasma cholesterol level in Japanese patients. Psychiatr Genet. 2005;15(4):239.
38.
ReynoldsCAHongMGErikssonUK. Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. Hum Mol Genet. 2010;19(10):2068–2078.
39.
PostmusITrompetSde CraenAJ. PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J Lipid Res. 2013;54(2):561–566.
40.
MeffordMTRosensonRSCushmanM. PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study [published online ahead of print]. Circulation. 2017. pii: CIRCULATIONAHA.117.029785.
41.
BennMNordestgaardBGFrikke-SchmidtRTybjærg-HansenA. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. BMJ. 2017;357:j1648.
42.
LiRSinghM. Sex differences in cognitive impairment and Alzheimer’s disease. Front Neuroendocrinol. 2014;35(3):385–403.
43.
BertramLMcQueenMBMullinKBlackerDTanziRE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17–23.
44.
GiauVVBagyinszkyEAnSSKimSY. Role of apolipoprotein E in neurodegenerative diseases. Neuropsychiatr Dis Treat. 2015;11:1723–1737.
45.
CreanSWardAMercaldiCJ. Apolipoprotein E ∊4 prevalence in Alzheimer’s disease patients varies across global populations: a systematic literature review and meta-analysis. Dement Geriatr Cogn Disord. 2011;31(1):20–30.
46.
NalbantogluJGilfixBMBertrandP. Predictive value of apolipoprotein E genotyping in Alzheimer’s disease: results of an autopsy series and an analysis of several combined studies. Ann Neurol. 1994;36(6):889–895.
47.
BlomDJHalaTBologneseM. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–1819.
48.
RidkerPMMoraSRoseL; JUPITER Trial Study Group. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37(17):1373–1379.
Weitz-SchmidtG. Statins as anti-inflammatory agents. Trends Pharmacol Sci. 2002;23(10):482–486.
53.
EckertGPHooffGPStrandjordDM. Regulation of the brain isoprenoids farnesyl- and geranylgeranyl pyrophosphate is altered in male Alzheimer patients. Neurobiol Dis. 2009;35(2):251–257.
54.
NozueTHattoriHOgawaKKujiraokaTIwasakiTMichishitaI. Effects of statin therapy on plasma proprotein convertase subtilisin/kexin type 9 and sortilin levels in statin-naive patients with coronary artery disease. J Atheroscler Thromb. 2016;23(7):848–856.
55.
GalaskoDHansenLAKatzmanR. Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch Neurol. 1994;51(9):888–895.
